abbisko therapeutics logo

Abbisko Therapeutics Co. Ltd.

Abbisko Therapeutics, focus on the development of immuno-oncology drugs to treat cancers that have a high incidence among Asian patient populations, such as lung, liver, stomach and esophageal cancers.

Abbisko is located in the Zhangjiang biotech cluster in Shanghai.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.abbisko.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Building 10th, 67 Li Bing Road, Zhangjiang Hi-Tech Park, Pudong New Area,20120
Shanghai
China
Email
Contact Number
+86 21-38122901

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Abbisko Therapeutics pipeline currently consisting of three preclinical compounds headed by lead candidate ABSK001, which is at the lead optimization stage.

In Feb 2017, Abbisko Therapeutics raised $28 Mn in a Series A financing; to advance its cancer immunotherapies program. The funding round was led by Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital and TF Capital.